Mnemo Therapeutics is a biotechnology company focused on discovering and developing immune based therapies, including powerful cell therapies, that create accessible cures for solid tumors and blood cancers. Its EnfiniT platform, a groundbreaking drug discovery engine, leverages a new class of antigens with greater tumor specificity and a suite of technologies to significantly improve T cell memory, persistence, and sensitivity. The result is dramatic improvement in the body’s immune response to overcome disease. Mnemo is built by a global team of scientists and biotech leaders united in their mission to create the most powerful immune therapies to deliver accessible cures for all patients in need.

Casdin Capital

Sofinnova Partners

Redmile Group

Alexandria Venture Investments

Emerson Collective

Mnemo Therapeutics

Our team strives to improve #CART cell efficacy and persistence to prevent cancer relapse. 

Two studies by Mnemo scientists and collaborators addressing this challenge were published in the journal Cancer Discovery (by AACR Journals) and featured on the issue's cover. Learn about the cover art and read the articles here:  https://lnkd.in/eCxZuJZ3

At this week's Keystone Symposia on Molecular & Cellular Biology's Emerging Cellular Therapies Conference, January 22-25 in Sante Fe, Theodoros Giavridis, Ph.D. and Michael Saitakis will present on e-antigens and CAR T cell persistence. For more info: https://lnkd.in/eeNNieeH #celltherapies #molecularbiology #cellularbiology #biotech #immunotherapy

The long-mysterious "dark genome" comprises 98% of the human genome and is considered not associated with protein-encoding exons, yet plays a role in a wide range of diseases. At the Dark Genome Symposium, Mnemo will present on grey genome derived MHC-presented peptides as a novel source of tumor-specific targets for #cancer immunotherapies. We look forward to connecting with others in biotech, academia and pharmaceuticals on efforts to illuminate the #darkgenome as we work to develop actionable therapeutics.

Our new study in collaboration with Institut Curie shows that ablating SUV39H1 enhances T cell memory and persistence, while reducing T cell exhaustion and protecting against tumor relapses in mouse models. Learn more: https://lnkd.in/eSyNRPK4

Learn the latest outcomes of epigenetic reprogramming of CAR T cells for functional persistence in solid tumors with Michael Saitakis, Associate Director, Immunotherapy at Mnemo, who will be presenting key scientific results at the VII Siena NIBIT Foundation Think Tank, organized in collaboration with The Parker Institute for Cancer Immunotherapy and the World Immunotherapy Council. Watch this video demonstrating why Mnemo's approach inactivates SUV39H1, an enzyme involved in the repression of memory-associated genes, to promote T cell persistence and defeat solid tumors.

We are thrilled to recognize Mnemo Scientific Co-Founder and Memorial Sloan Kettering Cancer Center physician-scientist Michel Sadelain, who has earned the Breakthrough Prize - the world's largest scientific prize - for his groundbreaking contributions in immunology, genetic engineering, and cell therapy. Dr. Sadelain's pioneering research is fundamental to Mnemo's technological approach. We congratulate Dr. Sadelain on this achievement and look forward to his continued work discovering new treatments for cancer. https://lnkd.in/eEPmuPMn

This year's DC BIOL 6th Course on Immunity and Cancer Immunotherapy event, sponsored by Mnemo and organized by Institut Curie and CIML, brought together a group of international participants for three days of fascinating lectures and discussions. Team Mnemo kept busy during the conference,
presenting the results of their research in three posters and participating in two discussions. Thank you to the event organizers and participants for an informative program.

A major challenge for cancer-specific therapeutics resides around specificity and recurrence of cancer targets. At the 6th Course on Immunity and Cancer Immunotherapy June 20-23, sponsored by Mnemo and organized by Institut Curie and CIML, Mnemo’s Nil Ege, PhD, sebastian amigorena, Michael Saitakis, Antonela Merlotti, PhD, Armelle Bohineust, yara el morr, and Louise Condon will present three posters and participate in two discussions. Learn more about how Mnemo is tackling these problems by discovering novel cancer targets while boosting immune activity to treat solid tumors.

Join us in congratulating Isabelle Rivière, PhD, Mnemo Scientific Co-Founder & Scientific Advisor and Justin Eyquem, PhD, Mnemo Scientific Co-Founder & Scientific Advisor on their recognition as American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting Award recipients!

We’re proud of the contributions and talent these individuals bring to Mnemo. Read more about all the 2023 ASGCT award recipients here: https://lnkd.in/eQyYvaNn

Mnemo Therapeutics is a biotechnology company focused on discovering and developing immune-based therapies, including powerful cell therapies, that create accessible cures for solid tumors and blood cancers. Its EnfiniT platform leverages a new class of antigens with greater tumor specificity and a suite of technologies to significantly improve T cell memory, persistence, and sensitivity, resulting in a dramatic improvement in the body’s immune response to overcome disease.

COM:MNEMO-TX

Mnemo Therapeutics

Filings Not Available